Partial Epigenetic Reprogramming Shows Early Promise in First Human Glaucoma Trial
Life Biosciences reports interim Phase 1 data for ER-100, an OSK gene therapy, in three glaucoma patients: it was well tolerated and two showed visual field gains.
Summary
Epigenetic reprogramming, a strategy aimed at resetting aged cells to a more youthful state, has reached its first human test in glaucoma. Life Biosciences released interim Phase 1 results for ER-100, a gene therapy that delivers three reprogramming factors (OCT4, SOX2 and KLF4, known as OSK) into the eye with a single injection. The factors are switched on by daily doxycycline pills for 56 days. In three adults with open-angle glaucoma, the lowest dose was well tolerated through Day 56, with no serious adverse events. The company reports that two of the three patients showed improved visual field test results. The safety monitoring board has cleared the trial to move to a higher dose. The numbers are tiny, the study is open-label, and the efficacy data come from the company rather than a peer-reviewed paper, so the results are preliminary. Still, they are an early signal for a whole field of aging biology.
Detailed Summary
Glaucoma is a leading cause of irreversible vision loss, and it is closely tied to aging. Current treatments lower eye pressure but cannot restore damaged retinal ganglion cells, the neurons that carry visual signals to the brain. That gap is why interim data from Life Biosciences' Phase 1 trial of ER-100 are drawing attention: it is among the first human tests of partial epigenetic reprogramming, an approach meant to reverse age-related changes in cells without erasing their identity.
The open-label trial enrolled three adults with open-angle glaucoma. Each received a single intravitreal injection of ER-100 at Dose Level 1 (2×10^11 vector genomes). The therapy delivers OCT4, SOX2 and KLF4 (OSK), and these genes are activated by daily oral doxycycline for 56 days. A prednisolone taper was used to limit inflammation risk.
Through Day 56 the company reported no dose-limiting toxicities, adverse events of special interest, or serious adverse events. It also said two of the three participants improved on Humphrey visual field testing, with at least 28 percent of tested points gaining more than 4 dB in each responder. The Data Safety Monitoring Board recommended escalating to Dose Level 2 (6×10^11 vg), and the trial (NCT07290244, started in the first quarter of 2026) continues.
The key insight is that a controllable, doxycycline-gated reprogramming system appears feasible and tolerable in human eyes at this early stage. This builds on animal work suggesting OSK expression can restore vision in damaged or aged retinal neurons.
There is nothing for readers to act on yet. This is an experimental therapy available only through a trial.
The caveats are substantial. Three patients is far too few to judge efficacy, and there is no control group. Visual field testing is variable and subject to learning effects, and the follow-up is only 56 days. The efficacy claims come from the company, not peer-reviewed publication. Durability, long-term safety and the risk of uncontrolled reprogramming remain open questions.
Key Findings
- ER-100 delivers OSK reprogramming factors via one eye injection, switched on by 56 days of oral doxycycline.
- Three glaucoma patients at the lowest dose had no serious adverse events or dose-limiting toxicities through Day 56.
- The company reports two of three patients improved on visual field testing, with 28%+ of points gaining over 4 dB.
- The safety board recommended escalating to a three-fold higher dose (6×10^11 vg); the trial is ongoing.
- With three patients, no control group and company-reported data, the efficacy signal is anecdotal and needs confirmation.
Methodology
This is a news report summarizing a company press release of interim data from an ongoing open-label Phase 1 trial (NCT07290244). Longevity.Technology is an industry-focused outlet, and the efficacy claims are attributed to the company. The evidence base is three participants with no control arm and no peer-reviewed publication.
Study Limitations
Only three patients were treated, with 56 days of follow-up, no placebo group and company-reported outcomes, so the efficacy signal could reflect test variability or chance. Details such as baseline severity, eye pressure changes and statistical analysis are not given. Verify results through the ClinicalTrials.gov record and any later peer-reviewed publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: